GlycoNex (ROCO:4168) Additional Paid-In Capital : NT$374.86 Mil(As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Additional Paid-In Capital?

GlycoNex's quarterly additional paid-in capital stayed the same from Sep. 2023 (NT$374.86 Mil) to Dec. 2023 (NT$374.86 Mil) and stayed the same from Dec. 2023 (NT$374.86 Mil) to Mar. 2024 (NT$374.86 Mil).

GlycoNex's annual additional paid-in capital increased from Dec. 2021 (NT$563.63 Mil) to Dec. 2022 (NT$587.47 Mil) but then declined from Dec. 2022 (NT$587.47 Mil) to Dec. 2023 (NT$374.86 Mil).

GlycoNex Additional Paid-In Capital Historical Data

The historical data trend for GlycoNex's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex Additional Paid-In Capital Chart

GlycoNex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

782.24

724.07

563.63

587.47

374.86

GlycoNex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															593.44	374.86	374.86	374.86	374.86

GlycoNex Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

GlycoNex Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of GlycoNex's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

GlycoNex (ROCO:4168) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221

Website

http://www.glyconex.com.tw

GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.

GlycoNex (ROCO:4168) Headlines

No Headlines